E ffective therapeutic development relies on the ability to prioritize the most promising targets at an early phase. Small molecules remain the predominant therapeutics for modulating intracellular targets. The challenges of developing compounds that are potent, selective and effective in vivo limit our ability to accurately predict the therapeutic potential of a candidate as well as on-target efficacy in a relevant disease model. Effective chemical probes need to be potent and selective for the target and also have a clear mode of action 1 . Genetic knockout or knockdown approaches, though selective, can produce phenotypes distinct from those seen with perturbation with a drug 2 . Thus, there remains an acute need for better technologies for facile validation of potential therapeutic targets in cells and animals.
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Mb(S4) potently inhibited the methyltransferase activity of the MLL1 core complex in a dose-dependent manner (Fig. 1b ). An in vitro pull-down experiment showed that Mb(S4) interacted with WDR5 and RbBP5, but not the MLL1 SET domain in the reconstituted MLL1 core complex, and its binding disrupted the WDR5-MLL1 interaction ( Supplementary Fig. 2a ). Because the Table 2 ) are shown as sticks. FG-loop residues are only partially labeled for clarity. The left panel shows the composite omit map (mF o − DF c ) contoured at the 2σ level for the contact residues of Mb(S4). c, The WDR5-MLL1 Win peptide complex (PDB ID 4ESG) 11 presented in the same manner and in the equivalent orientation as in b. Residues 3760-3770 of the MLL1 peptide are shown. d, Detailed representation of the WDR5 interaction with the MLL1 WIN motif 11 , FG-loop residues of Mb(S4) and MM-401 (ref. 15 ). WDR5 residues are labeled in red, and MLL1 WIN motif, Mb(S4) and MM-401 residues in black. Salt bridges and hydrogen bonds are shown as dotted black lines. e, Overlay of WDR5-interacting residues of Mb(S4) (in cyan) with the MLL1 WIN motif (magenta, left panel) and with MM-401 (magenta, right panel). The overlapping residues between the WIN motif and Mb(S4) are indicated as uppercase letters in the sequence alignment.
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NATuRe CHeMiCAL BioLogy WDR5-MLL1 interaction pocket was also involved in histone H3 binding 24 , we found that Mb(S4) disrupted the interaction of WDR5 with histone H3 peptide as expected ( Fig. 1c ). Taken together, these results suggest that Mb(S4) disrupts the MLL1 core complex by binding to the Win/H3-binding pocket of WDR5.
Structural basis of monobody-WDR5 interaction.
To further define the mechanism of action of Mb(S4), we determined the crystal structure of the WDR5-Mb(S4) complex at 2.7 Å resolution ( Fig. 2a ; Supplementary Table 1 ). Both monobody and WDR5 retained their respective overall fold (Cα r.m.s. deviation of 1.0 Å for Mb(S4), excluding the diversified loops of the monobody, and 0.8 Å for WDR5). As expected, Mb(S4) bound to the central cavity of WDR5, where the Win motif binds ( Fig. 2a ). Mb(S4) occupies surfaces of WDR5 that are remarkably similar to those occupied by the MLL1 Win peptide 11 (Fig. 2b,c) . Both interfaces include a total of 26 WDR5 residues, and 20 residues are shared between them (Supplementary Table 2 ). The sizes of their interface are nearly identical (699 versus 687 Å 2 , respectively). Thus, Mb(S4) effectively sequesters the surfaces of WDR5 that are used for binding to the MLL1 Win peptide and other ligands for this pocket.
Residues in the FG loop of Mb(S4), which was the most extensively diversified monobody in the library ( Supplementary Fig. 1a ), make most contacts with WDR5 ( Fig. 2a,b ). Strikingly, the monobody inserted its Arg80 side chain in the cavity in a manner similar to Arg residues of previously identified ligands, such as the Win motif of MLL1 and a histone H3 peptide 9,24-26 , as well as the guanidine group of MM-401 ( Fig. 2d ; Supplementary Fig. 2b) 12, 16, 22, 27 . The binding modes of monobody, the Win peptide and MM-401 into this cavity are remarkably similar ( Fig. 2e ). Mb(S4) used additional residues in the FG loop, H31 in β -strand C and K49 in β -strand D to contact WDR5 ( Fig. 2a,b) .
To confirm the observed interaction and prepare a closely matched negative control, we replaced Arg and Trp residues of Mb(S4) that make extensive interactions with WDR5 with Asp and Ala, respectively (R80D/W81A). The binding of the mutant protein, Mb(S4mut), to WDR5 was undetectable ( Supplementary Fig. 2c,d ). Consistently, Mb(S4mut) did not inhibit MLL1 methyltransferase activity ( Fig. 1b ) or interact with WDR5 in the MLL1 core complex in vitro ( Supplementary Fig. 2a ). In addition, a charge reversal mutation, K49E, strongly reduced the binding of Mb(S4) to WDR5 ( Supplementary Fig. 2c ), suggesting that residues outside the FG loop also contribute to the monobody-WDR5 interaction. Mb(S4) has much higher affinity than the MLL1 Win peptide, whose K D is in the low micromolar range 11 . We speculate that the constrained conformation of the FG loop, as oppose to the inherently disordered nature of a linear peptide such as the Win peptide, may favorably contribute to the high affinity because of a smaller loss of the conformational entropy upon binding.
WDR5 interacts with another core component of the MLL complex, RbBP5, using surfaces distant from the Win-binding site. Binding of Mb(S4) did not affect the affinity of the WDR5-RbBP5 interaction ( Supplementary Fig. 3a ). The conformation of WDR5 in the WDR5-Mb(S4) complex was nearly identical to those of WDR5 in complexes wherein a ligand is bound to the RbBP5-binding pocket ( Supplementary Fig. 3b ). These results indicate that Mb(S4) does not allosterically affect the WDR5-RbBP5 interaction.
Mb(S4) inhibits MLL1-dependent gene expression.
To utilize Mb(S4) as a genetically encoded intracellular inhibitor, we first evaluated the specificity of Mb(S4) in the context of the cellular proteome. Mb(S4) captured a major band at ~36 kDa from whole-cell lysate or nuclear extracts of HEK293-T cells ( Supplementary Fig. 4 ), which was confirmed to be WDR5 by MS analysis (Supplementary Dataset 1). The negative control monobody, Mb(S4mut), did not capture WDR5 or other proteins associated with the MLL family 
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enzymes in any sample we tested. These results demonstrate that Mb(S4) interacts with WDR5 in cells with high specificity.
We next examined the function of Mb(S4) on MLL1-dependent gene expression. First, we expressed the Mb(S4)-EGFP fusion gene in HEK293-T cells by transient transfection. We found dose-dependent repression of HOXA9 gene expression, a well-known MLL1 target, by the Mb(S4)-EGFP fusion ( Supplementary Fig. 5 ). In contrast, expression of Mb(S4mut) had a much weaker effect. Next, we tested the effects of Mb(S4) and Mb(S4mut) on Hoxa9 gene expression in the murine MLL-AF9 leukemia cell line 15 . To minimize potentially Images are representative of n = 3 independent mice. d, Cytological Giemsa staining of bone marrow cells isolated 40 d post-transplantation; cells from nontransplanted mice were included as a normal control. Images are representative of n = 3 independent mice. e, RT-qPCR for HoxA7, HoxA9, Deptor, Bcl11a, Celf4 and Egr2 in primary bone marrow cells isolated from MAF9-S4, MAF9-S4mut and MAF9 mice treated with or without TMP. Gene expression was normalized against Gapdh and was presented as fold change against that of MLL-AF9 cells, which was arbitrarily set to 1. Data are presented as mean ± s.d. from three independent experiments. f, ChIP-qPCR analyses for H3K4me1 at MLL1 binding sites for HoxA7, HoxA9, Deptor, Bcl11a, Celf4 and Egr2 in bone marrow cells isolated from MAF9-S4, MAF9-S4mut and MAF9 mice with or without TMP treatment. The data was normalized against 5% input and presented as mean ± s.d. from n = 3 independent experiments.
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NATuRe CHeMiCAL BioLogy toxic effects of the monobodies, we used a DHFR degron-based inducible system to control their expression 28 . Here, the monobody is fused between a destabilized DHFR variant and EGFP, and the fusion protein is degraded in the absence of the DHFR ligand trimethoprim (TMP) and is stabilized by TMP. Fusion of Mb(S4) with DHFR and EGFP did not influence its binding to WDR5 ( Supplementary  Fig. 6a ). Mb(S4) or Mb(S4mut) as the fusion protein also did not affect expression of WDR5 or other MLL core components in cells ( Supplementary Fig. 6b ). Induction of Mb(S4) by addition of TMP resulted in a 50% reduction of Hoxa9 expression in MLL-AF9 cells (Fig. 3a ). This level of reduction, albeit moderate, is similar to what was reported for the small-molecule inhibitor MM-401, as well as MLL1 genetic deletion 15 , suggesting that Mb(S4)-EGFP was fully engaged with WDR5 and effectively blocked the WDR5-MLL1 interaction as well as its downstream gene expression in cells.
To test whether disruption of the WDR5-MLL1 interaction by Mb(S4) inhibits proliferation of leukemia cells, we performed a competitive growth assay in which cells with or without monobody expression were mixed in a 1:1 ratio, and the relative ratio of the two populations (GFP + vs. GFP − ) was determined at different time points by flow cytometry. Expression of Mb(S4), but not Mb(S4mut), had a profound inhibitory effect on the proliferation of MLL-AF9 cells (Fig. 3b ). In contrast, Mb(S4) did not affect proliferation of MLL1 independent E2A-HLF leukemia cells ( Fig. 3c ; Supplementary  Fig. 7a,b ). Thus, targeting the WDR5-MLL1 interaction by Mb(S4) specifically inhibited proliferation of MLL1-dependent leukemia cells, confirming previous results by the small-molecule inhibitors 15, 22 . We further tested the effect of Mb(S4) on clonogenicity of MLL-AF9 cells on methylcellulose medium. Mb(S4), but not Mb(S4mut) or another nonbinding monobody, Mb(FNsh), significantly reduced colony formation capability of the MLL-AF9 cells. It induced significant differentiation of leukemic blasts toward myeloid lineages ( Fig. 3d ,e; Supplementary Fig. 7c ).
Mb(S4) suppresses leukemogenesis.
Having established genetically encoded Mb(S4) as a potent and selective inhibitor of WDR5-MLL1 interaction, we next used it to examine the therapeutic potential of targeting the WDR5-MLL1 interaction in the MLL-AF9 leukemia model in vivo. To this end, we engrafted lethally irradiated mice with MLL-AF9 cells (termed MAF9) or MLL-AF9 cells expressing TMP-inducible Mb(S4) (termed MAF9-S4) or TMP-inducible Mb(S4mut) (termed MAF9-S4mut). Similar engraftment efficiency was found for all experimental groups 48 h post-transplantation. At two weeks post-engraftment, when the hematopoietic compartment was reconstituted with engrafted cells, trimethoprim/sulfamethoxazole (TMP/SMX) was administered for 10 consecutive days to induce monobody expression. Induction of Mb(S4) significantly increased leukemia latency and resulted in substantial benefit in survival compared to that of mice recipients of MAF9-S4mut cells ( Fig. 4a ; P < 0.0001). Notably, there was a significant difference in survival curve between the MAF9 and MAF9-S4mut mice. This difference was probably due to a lower percentage of leukemia stem cells (LSK + ) in the MAF9-S4mut cells relative to the parental MAF9 cell culture (Fig. 4a ). Viral transduction with a corresponding empty vector that does not express a DHFR-Mb-GFP fusion also decreased the percentage of leukemia stem cells ( Supplementary  Fig. 8 ). Because engrafted MAF9-S4mut cells had higher amounts of LSK + cells than the MAF9-S4 cells yet they died earlier, it is likely that the survival benefit of Mb(S4) compared to Mb(S4mut) mice was underestimated in our study.
Consistent with leukemia development in vivo, spleens from MAF9-S4mut mice 40 d post-implantation, when the first MAF9 mouse became morbid, were larger than those of MAF9-S4 mice (Fig. 4b ). There were also significant increases in myeloblast counts in the bone marrow as well as myeloblast infiltration in liver and spleen of MAF9-S4mut mice in comparison to MAF9-S4 mice ( Fig. 4c ; Supplementary Fig. 9a,b ). Histology of blood cells isolated from MAF9-S4 mice 40 d after transplantation showed that although significant numbers of undifferentiated myeloblasts were observed in the peripheral blood of MAF9 and MAF9-S4mut mice ( Fig. 4d ), differentiated myeloid cells were only found in the peripheral blood of MAF9-S4 mice (Fig. 4d ). Flow cytometry analysis further confirmed the marked reduction of the CD11b + /Gr-1 + leukemia blasts in bone marrow of the MAF9-S4 mice relative to the MAF9-S4mut and the MAF9 mice ( Supplementary Fig. 9c ). Taken together, these results indicate that inhibition of the WDR5-MLL1 interaction delays the onset of MLL-AF9 leukemia and increases survival benefit in vivo.
Molecular analyses of MAF9 cells isolated 40 d post-engraftment support the mechanism of action of Mb(S4) in inhibiting leukemogenesis. Mb(S4) expression downregulated several well-established MLL1 direct targets; for example, Hoxa7, Hoxa9, Deptor, Bcl11a and Egr2 (Fig. 4e ). There was 35-55% reduction of H3K4me1 at known MLL1 binding sites near these genes in MLL-AF9 cells expressing Mb(S4) (Fig. 4f ). In contrast, no significant reduction of H3K4me1 was found in MLL-AF9 or MLL-AF9 cells expressing Mb(S4mut).
Discussion
Our study here provides a critical proof of concept that validates the survival benefit of targeting WDR5 in vivo. The use of inducible and genetically encoded inhibitors circumvents the major challenge of making chemical probes sufficiently potent, selective and bioavailable for target engagement in animal models. The strong tendency of monobodies to bind to a functional site within a protein and their ability to bind to diverse surface topography including virtually flat surfaces 3 suggest that one can identify monobody inhibitors against many targets without extensive effort. Their effectiveness as crystallization chaperones also helps establish their mechanism of action 29 . Although the specific goal of this study is to validate the efficacy of targeting a known druggable site, our strategy can be readily expanded for discovering and validating new druggable targets. Indeed, our recent success in identifying a monobody that binds to an allosteric site of RAS and inhibits RAS-mediated signaling 30 suggests that one could identify a new druggable site even in an extensively studied protein. Whereas this study was designed to address on-target, on-tissue efficacy, systemic expression in transgenic animals could address off-tissue toxicity. Thus, we propose that our approach is generally applicable for establishing the bestcase-scenario outcome for specific perturbation of the target of interest in vivo and is a valuable tool for making the go or no-go decision in drug discovery at an early stage.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0099-z.
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Methods
Protein expression and purification. Expression vectors for human WDR5
(residues 1-334) with an N-terminal His 6 tag and a C-terminal biotin-acceptor tag and for human RbBP5 (full length) with an N-terminal biotin-acceptor tag and a C-terminal His 6 tag were kindly provided by S. Gräslund and C. Arrowsmith (Structural Genomics Consortium). Monobodies were produced using the pHBT vector with N-terminal His 6 and biotin-acceptor tags 31 . The proteins were produced in BL21(DE3) cells containing the pBirAcm plasmid in the presence of 50 μ M biotin to produce biotinylated proteins.
Proteins were purified using Ni-Sepharose gravity flow columns (GE Healthcare) and monodispersity of these proteins was assessed using size-exclusion chromatography columns (GE Healthcare). Supplementary Fig. 10 shows the purity of proteins used in biochemical assays. For crystallization, the fusion tags were removed using tobacco etch virus (TEV) protease cleavage and Ni-Sepharose columns.
Phage display and yeast display-based selection. The method of generating monobodies has been previously described 23 . Two monobody libraries ('loop' and 'side'; Supplementary Fig. 1a ) were used to generate monobodies with diverse binding modes 23 . Each of these libraries contains approximately 10 billion unique monobody clones in which 16-26 residues are diversified using highly tailored amino acid combinations 23 . Selection details were followed as described 32 .
Bead-based binding assays. The general methods for bead-based assays have been described 33 . The assay design was followed as previously described 32 .
In vitro methyltransferase assay. Monobodies were tested in histone methyltransferase (HMT) reaction buffer consisting of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 10% glycerol. Human MLL1 SET domain, WDR5, RbBP5 and ASH2L were mixed in equal stoichiometry to form the active MLL1 complex at a final concentration of 125 nM. Different amounts of monobodies were mixed with MLL1 complex and incubated on ice for 10 min before initiation of HMT reaction with 1 µ M of 3 H-SAM (S-adenosylmethionine) and 4 µ M of histone H3 (1-21) peptide. HMT reactions were allowed to proceed for 1 h at 22 °C and terminated by spotting 10 µ L of reaction mixture onto Whatman P81 ion exchange filter paper. The filter paper was air dried and washed in three 10-min washes in 50 mM sodium bicarbonate pH 9.0 to remove excess SAM. Filter paper was heat-dried for 20 min and placed in 10 mL Ultima Gold scintillation fluid for 3 H signal acquisition in the unit of counts per minute (c.p.m.). Note that the K D value of WDR5-Mb(S4) interaction (5 nM) is much lower than the concentration of MLL1 complex necessary for the assay and therefore a relevant IC 50 value cannot be derived from the data shown in Fig. 1 . The purpose of this experiment is instead to show dosedependent inhibition.
HEK293-T cell transfection. HEK293-T cells were cultured in Dulbecco's
Modified Eagle's Medium supplemented with 10% FBS and antibiotic-antimycotic mix (Gibco). Cells were transfected with expression vectors encoding the monobody-EGFP fusion proteins using polyethylenimine (PEI) or Hilymax (Dojindo). Cells were harvested 48 h after transfection, checked for monobody-EGFP expression using flow cytometry and then used to prepare RNA using Trizol.
Immunoprecipitation. Biotinylated Mb(S4) or Mb(S4mut) (150 pmol) and 50 μ l of prewashed DynaBeads M-280 (Thermo Fisher) were used for immunoprecipitation experiments. Whole-cell lysate or nuclear extract was prepared from wild-type HEK293-T cells. Whole-cell lysates or nuclear extracts were precleared with M-280 Dynabeads to eliminate proteins that bind nonspecifically to the beads before incubating with monobody-immobilized Dynabeads for 2 h at 4 °C with rotation. The Dynabeads were washed four times with 20 mM Tris-HCl buffer pH 8.0 containing 480 mM NaCl, 5 mM MgCl 2 , 0.1% sodium deoxycholate and 0.5% NP-40, with 10 min incubation for each wash step. The immunoprecipitated proteins were eluted from the M280 beads by boiling the beads in 10 mM Tris-HCl buffer pH 8.0 containing 150 mM NaCl and 0.1% SDS for 5 min. The eluted proteins were characterized by SDS-PAGE detected with silver staining and by mass spectrometry at the NYU School of Medicine Proteomics Laboratory.
Crystallization of WDR5/Mb(WDR5_S4) complex.
Purified WDR5 (residues 31-334) and Mb(S4) proteins were mixed in the molar ratio of 1.0:1.5, and the complex was purified using a Superdex75 16/600 size-exclusion chromatography column (GE Healthcare) in 25 mM Tris pH 8.0, 150 mM NaCl and 0.2 mM TCEP. The protein complex was concentrated to a final concentration of 12.5 mg/ml. Initial crystallization screening of ~500 conditions was carried out in 96-well plates using the hanging-drop vapor-diffusion method with a crystallization robot (Mosquito, TTP Labtech). Crystals used for data collection were obtained in 0.1 M Bis-Tris HCl buffer pH 5.5 containing 28% PEG3350, cryoprotected with 21% glycerol and flash cooled in liquid nitrogen before data collection.
Data collection, structure determination and refinement. X-ray diffraction data were collected at Beamline 19ID at the Advanced Photon Source (Argonne National Laboratory, Chicago, IL, USA) at a wavelength of 0.9792 Å and at 100 K. Data collection information is reported in Supplementary Table 1 . The data were indexed and integrated using HKL3000 (ref. 34 ). Molecular replacement using MOLREP 35 with WDR5 (PDB ID 2H9N) resulted in a solution with a contrast of 24.3. This solution was fixed to search for Mb(S4) using a monobody structure with excluded loop regions from the PDB ID 3UYO. The resulting solution had a contrast of 10.9, indicating a definite solution. Iterative model building and refinement were done using the programs COOT 36 and PHENIX 37 . The final structures were analyzed using the programs PROCHECK 38 and Molprobity 39 . The final structural model was of good geometry, with 96% of residues in favored regions and 4% in allowed regions of the Ramachandran analysis. Figures were prepared using PyMOL (Schrödinger).
Retroviral transduction of leukemia cells.
Plat-E cells were transfected with pMSCV-based vectors encoding DHFR-Mb(S4)-EGFP, DHFR-Mb(S4mut)-EGFP or no insert (empty vector) using Lipofectamine (Invitrogen). The retroviral supernatant was harvested after 48 h and 72 h, filtered and added to leukemia cells derived from mouse bone marrow along with 1:1,000 polybrene (Millipore). The virus-cell mixture was centrifuged at 3,200 r.p.m. for 90 min using a swing-bucket rotor. The cells were then incubated at 37 °C in a CO 2 incubator. To improve the efficiency of transduction, the infection was repeated once. The transduced leukemia cells were selected in the presence of 10 μ g/ml Blasticidin. Leukemia cells were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 15% FBS and 10 ng/ml interleukin-3 (IL-3) at each passage. To induce monobody expression, 10 μ M of trimethoprim was added. The transduced cells were sorted using a FACSAria II (BD Biosciences) to isolate monobody expressing cells.
Binding measurement of the DHFR-Mb-EGFP fusion proteins. HEK293-T cells transfected with the pMSCV vectors encoding DHFR-Mb(S4)-EGFP or DHFR-
Mb(S4mut)-EGFP were grown in the presence of 10 μ M TMP, harvested and lysed in 10 mM Tris-HCl buffer pH 8.0 containing 420 mM NaCl and 0.1% NP40. The fusion proteins were captured onto DynaBeads M-280 conjugated with biotinylated EGFP-binding monobody 23 . Binding of WDR5 was measured using the bead-based binding assays 33 .
Cell-growth assay. Transduced leukemia cells were mixed with nontransduced leukemia cells in a 1:1 ratio. The mixed cells were grown in IMDM supplemented with 15% FBS and 1× antibiotic-antimycotic (Gibco) containing 0.01% DMSO or 10 μ M TMP. The cells were passaged every 24 h. Cells were washed and resuspended in PBS before flow cytometry analysis. Similarly, transduced 3T3 cells were mixed with nontransduced cells and grown in high-glucose DMEM supplemented with 10% FBS in multiple wells. For each time point, cells were detached by trypsin, washed and resuspended in PBS. The fraction of monobodyexpressing cells was determined by monitoring for GFP and/or mCherry on LSR Fortessa analyzer (BD Biosciences) or Guava easyCyte BGR (Millipore). Data were analyzed with the FlowJo software (Treestar).
RT-qPCR expression analysis.
Total RNA was extracted from cells using Trizol and purified using the RNA Clean and Concentrator kit (Zymo Research). For cDNA preparation, we used DNase-digested RNA, random hexamer primers and the SuperScript III Reverse Transcriptase (Invitrogen). After the RT reaction, the cDNA was purified using the QIAquick PCR purification kit (Qiagen). The primers used for qPCR were as follows:
We performed qPCR using the SsoAdvanced Universal SYBR Green Supermix (Bio-Rad), on a CFX384 Touch Real-Time PCR detection system (Bio-Rad).
Western blotting. Western blotting was done according to standard laboratory procedures. The following antibodies were used: anti-WDR5 (A302-430A; 1:2,000), MLL1 (ref. 37 ), ASH2L (A300-489A; 1:5,000), RbBP5 (A300-109A; 1:5,000) and anti-Calnexin (H-70; 1:1,000). The bands were analyzed using chemiluminescence on a ChemiDock imager (Bio-Rad). We quantified the band intensities using ImageLab (Bio-Rad), with data normalized based on the Calnexin signal.
Mouse experiments. Forty of the 4-6-week-old female C57BL/6 mice were randomly grouped into three groups, each containing 12 mice, lethally irradiated (900 rad) and transplanted through tail vein intravenous injection with 5 × 10 6 MLL-AF9, MLL-AF9 + Mb(S4) and MLL-AF9 + Mb(S4-mut) cells. Four mice were assigned as radiation control. Two weeks post-transplantation, each group of mice was treated with or without TMS for ten consecutive days. TMS (200 mg/ml T: 40 mg/ml S per 5 ml) was applied twice daily via oral gavages. The mice were monitored for 5 months for signs of acute leukemia. Body weight was monitored daily during the treatment and at least 3 times a week after treatment. Moribund mice were dissected. Spleen and bone marrow cells were harvested and frozen. Leukemia was confirmed based on flow cytometry analysis of leukemia blast cells in spleen, bone marrow and liver as well as by histopathology.
For histopathology detection, tissues were fixed in 10% formalin and submitted for sectioning to the Pathology Cores for Animal Research. Photographs of sections were taken using 2× , 40× and 50× objectives with an Olympus BX-51 microscope. Bone marrow cells were isolated by flushing both femurs and tibias with IMDM with 2% FBS. Single-cell cytospins were stained with the Giemsa stain.
For the analysis of myeloid cell population in mice, bone marrow cells isolated from transplanted mice or normal mice were prepared as single-cell suspensions in flow cytometry buffer (PBS with 1% BSA, 10 mM HEPES and 0.01% NaN 3 ), stained on ice with CD11b and Gr-1 antibodies and subjected to flow cytometry analysis. For analysis of leukemia stem cells, Lin − MAF9, MAF9-S4 and MAF9-S4mut (2 × 10 6 cells each) were washed with PBS twice and resuspended in 500 μ l of PBS. 90 µ l of cell suspension were mixed with 1 μ g each of FITC-conjugated Sca1 antibody (E13-161.7, BioLegend) and APC-conjugated c-kit antibody (2B8, BioLegend) separately or in combination, and cells without antibody were used as a negative control. After incubating on ice for 30 min, 75 μ l of PBS was added to each well and centrifuged at 400g for 7 min. Samples were washed once with PBS and then fixed in 200 μ l of 2% paraformaldehyde and analyzed on a flow cytometer within 24 h.
Colony formation assays and cytospins. Retroviral production and transduction of bone marrow progenitor cells were carried out as described 15 . Briefly, Plat-E cells were transfected using Fugene 6 with the pMSCV vectors encoding MLL-AF9, DHFR-Mb(S4)-EGFP, DHFR-Mb(S4mut)-EGFP and DHFR-Mb(FNsh)-EGFP as the nontarget control. FNsh is a negative control monobody in which all the residues in the BC, DE and FG loops ( Supplementary Fig. 1a ) are replaced with Ser. After 48 to 72 h post-transfection, the supernatants were collected and used for transduction of bone marrow progenitor cells prepared as follows: 10-weekold C57BL/6 mice were injected intravenously with 5-fluorouracil (150 mg/kg), and bone marrow (BM) progenitor cells were harvested from both femurs at 3 d post-injection. After hematopoietic progenitor enrichment, retroviral supernatant for MLL-AF9 in combination with the retroviral supernatant for DHFR-Mb(S4)-EGFP, DHFR-Mb(S4mut)-EGFP and DHFR-Mb(FNsh)-EGFP were used to cotransduce BM cells by spinoculation. Two days after infection, the infected cells were selected using blastocidin (10 µ g/ml) and G418 (1 mg/ml). Two days after selection, infected cells were plated into methylcellulose cultures with or without TMP (10 µ M). After the third round of plating, cells were collected and subjected to Wright-Giemsa-stained cytospins.
Real-time PCR and ChIP assays of mouse bone marrow cells.
Primary mouse bone marrow cells were isolated 40 d after transplantation from MAF9-S4, MAF9-S4mut and MAF9 mice treated with or without TMP for 10 d. Cells were harvested by centrifugation at 300g and washed with 1× PBS. RNAs for duplicated biological samples were extracted by a standard protocol. ChIP assays were performed as previously described 40 . Primers used were: The sample size was determined by our experience that the injected mice develop leukemia in 30 days with a standard deviation of 10 days. If the time to occurrence of leukemia is extended to 40 days with a power of 90% and a significance level of 5%, then the difference to be detected is 10 days and the group size n=1 +21(10/10)^2=22; animals in each group for transplantation with MLL-AF9, DHFR-WDR5 and DHFR-WDR5 mutant respectively (3x22=66). These mice were divided into two groups, with 11 mice in each group, for TMS treated and untreated. 
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
40 of 4-6 week old female C57BL/6 mice were randomly grouped after lethal irradiation (900rads) with each group (MAF9-S4, MAF9-S4mut and MAF9) containing 12 mice. The remaining 4 mice were using as control for lethal irradiation. The lethally irradiated mice were transplanted through tail vein intravenous injection with about 5X106 MAF9 cells, MAF9-S4 and MAF9-S4mut cells for each group. This experiment was repeated one more time.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Single blinding was used for the animal experiments. The experimental performers were unaware of the subject. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials generated and used in this manuscript will be readily available from the authors.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
10. Eukaryotic cell lines a. State the source of each eukaryotic cell line used. Cell line prepared by transducting mouse bone marrow derived cells with MLL-AF9 fusion protein was used in the study. This cell line was further transduced with retroviral vectors encoding our monobody inhibitor.
b. Describe the method of cell line authentication used. Stable cell line expresses mCherry protein constitutively and was used as a marker for cell line authentication.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cell lines were tested to be free of mycoplasma contamination using MycoAlert PLUS mycoplasma detection kit (Lonza, catalog number LT07-710). In addition, all media were supplemented with Gibco's antibiotic-antimycotic (Catalog number: 15240062)
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
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Description of research animals
Provide details on animals and/or animal-derived materials used in the study. 80 4-6 week old female C57BL/6 mice (weight mean 22.28g with s.d. 1.07g) were purchased from Charles River laboratories and the Unit for Laboratory Animal Medicine (ULAM) of University of Michigan provided husbandry and housing for these mice. The mice used in the study were specific pathogen free. Immortalized MLL-AF9 leukemia cells that expressing DHFR fused with WDR5-targeting monobody or monobody mutant under the control of the TMS-inducible promoter (5 million cells) with the volume of 100ul were injected into tail vein of the lethally irradiated mouse, which is expected to develop leukemia within 4-6 weeks after transplantation. Immediately after irradiation, the mice were fed with 0.2mg/mL of enrofloxacin (Baytril) water for 1 week to prevent irradiation caused infection. The water supply was monitored every 3-4 days. Mice were closely monitored daily for sign of illness (e.g. reduced motility, hind limb paralysis, pale paws, hunched back, reduced weight), which will be end point of the study. About two weeks after transplantation the animals were randomized and treated with TMS via oral gavages at 20mg/20g twice daily for 10 days. ULAM provided this oral gavages service. Body weight was monitored daily during the treatment and at least 3 times a week after treatment. Peripheral blood (20 to 40 ul per sample) was checked twice a week by Fluorescence Activated Cell Sorting (FACS) to detect leukemia progression by assessment of GFP+ cells, increase in white blood cell count, and presence of immature forms of blood. Animals were euthanized by carbon dioxide overdose when they became moribund as described above. Spleen, liver, hind leg bone and bone marrows were collected. Leukemia was confirmed based on flow cytometry analysis and by histopathology. Note: TMS is commonly used in rodents for infection treatment.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
The study did not involve human research participants.
